Form 4: Lantheus Grants R&D Head Stock & Options

Lantheus Holdings, Inc. granted its Head of Research and Development, Ludger Dinkelborg, 14,765 restricted stock units and 25,324 stock options.

Summary

• Ludger Dinkelborg, Head of Research and Development at Lantheus Holdings, Inc. (LNTH), acquired 14,765 shares of common stock through a grant of restricted stock units (RSUs) on August 15, 2025.
• These 14,765 RSUs will vest in equal installments over a three-year period.
• Dinkelborg also acquired 25,324 stock options with an exercise price of $54.18 on August 15, 2025.
• The stock options will vest in three equal annual installments beginning on August 15, 2026, and have an expiration date of August 15, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation grant, which is generally positive as it aligns management's interests with shareholders. It does not contain negative news or significant unexpected events.

Positives

• The grant of restricted stock units and stock options to a key executive like the Head of Research and Development aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• Equity compensation is a standard practice for attracting and retaining top talent in the pharmaceutical and biotechnology sectors.

Future Outlook

The restricted stock units are set to vest in equal installments over a three-year period. The stock options will vest in three equal annual installments, commencing on August 15, 2026, and will expire on August 15, 2035.

Industry Context

The grant of equity compensation, including restricted stock units and stock options, to senior executives is a common and widely accepted practice across the biotechnology and pharmaceutical industries. This approach is used to align executive incentives with long-term shareholder value creation and to ensure competitive compensation packages for key talent.

Comparison to Industry Standards

• The structure of this equity grant, involving both restricted stock units (RSUs) and stock options with multi-year vesting schedules, is consistent with typical executive compensation practices observed in comparable life sciences companies.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar equity-based incentives to retain and motivate their research and development leadership, ensuring their commitment to long-term innovation and pipeline success.

Related Party Transactions

• The acquisition of restricted stock units and stock options by Ludger Dinkelborg, an officer (Head of Research and Development) of Lantheus Holdings, Inc., represents a related party transaction in the form of executive compensation.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability and commitment from leadership, potentially boosting morale.
• Executive (Ludger Dinkelborg): Directly benefits from equity compensation, providing a significant incentive for long-term performance.

Next Steps

• Continued vesting of 14,765 restricted stock units over a three-year period.
• Commencement of stock option vesting in three equal annual installments starting August 15, 2026.

Key Dates

Keywords

Lantheus Holdings, LNTH, SEC Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Grant, Research and Development